Condition: Pregnancy · Preeclampsia (PE) · Sponsor: University of Mississippi Medical Center
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
This description comes directly from the study's public registry record.
Babbette LaMarca, PhD · (601)815-1430 · bblamarca@umc.edu
Lorena M Amaral, Ph.D. · lmamaral@umc.edu
Always discuss trial participation with your own doctor first.
| Winfred L. Wiser Hospital | Jackson, Mississippi, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02989025